Published in Thromb Haemost on February 02, 2010
Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol (2014) 2.17
Recommendations for the implementation of a Patient Blood Management programme. Application to elective major orthopaedic surgery in adults. Blood Transfus (2015) 1.46
Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16
Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J (2013) 1.15
New anticoagulants: how to deal with treatment failure and bleeding complications. Br J Clin Pharmacol (2011) 1.11
Approach to the new oral anticoagulants in family practice: part 2: addressing frequently asked questions. Can Fam Physician (2014) 1.07
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05
Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet (2014) 1.05
New anticoagulants: A concise review. J Trauma Acute Care Surg (2012) 1.04
Facts and artefacts of coagulation assays for factor Xa inhibitors. Thromb Haemost (2010) 0.97
Non-VKA Oral Anticoagulants: Accurate Measurement of Plasma Drug Concentrations. Biomed Res Int (2015) 0.95
Determination of rivaroxaban by different factor Xa specific chromogenic substrate assays: reduction of interassay variability. J Thromb Thrombolysis (2011) 0.94
Coagulation assessment with the new generation of oral anticoagulants. Emerg Med J (2015) 0.93
New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Des Devel Ther (2014) 0.92
The new oral anticoagulants and the future of haemostasis laboratory testing. Biochem Med (Zagreb) (2012) 0.92
Bivalirudin in combination with heparin to control mesenchymal cell procoagulant activity. PLoS One (2012) 0.91
Anticoagulants and the propagation phase of thrombin generation. PLoS One (2011) 0.89
Stroke prevention in atrial fibrillation: understanding the new oral anticoagulants dabigatran, rivaroxaban, and apixaban. Thrombosis (2012) 0.87
Clinical review: Clinical management of new oral anticoagulants: a structured review with emphasis on the reversal of bleeding complications. Crit Care (2013) 0.87
New oral anticoagulants for atrial fibrillation: are they worth the risk? P T (2014) 0.87
Stroke prevention in atrial fibrillation: concepts and controversies. Curr Cardiol Rev (2012) 0.86
Anticoagulation intensity of rivaroxaban for stroke patients at a special low dosage in Japan. PLoS One (2014) 0.86
Reversal of oral anticoagulation. Pharmacotherapy (2013) 0.82
Anticoagulant therapy for patients with ischaemic stroke. Nat Rev Neurol (2012) 0.82
Use of novel oral anticoagulant agents in atrial fibrillation: current evidence and future perspective. Cardiovasc Diagn Ther (2014) 0.81
Thrombelastography detects the anticoagulant effect of rivaroxaban in patients with stroke. Stroke (2014) 0.80
Interrupting anticoagulation in patients with nonvalvular atrial fibrillation. P T (2014) 0.80
Practical management of new oral anticoagulants after total hip or total knee arthroplasty. Musculoskelet Surg (2013) 0.80
Venous thromboembolism: EINSTEIN transforms anticoagulant therapy in acute PE. Nat Rev Cardiol (2012) 0.79
Rivaroxaban and apixaban in orthopaedics: is there a difference in their plasma concentrations and anticoagulant effects? Blood Coagul Fibrinolysis (2015) 0.78
Measurement of rivaroxaban and apixaban in serum samples of patients. Eur J Clin Invest (2014) 0.78
Oral anticoagulants in the management of venous thromboembolism. Nat Rev Cardiol (2013) 0.78
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest (2016) 0.78
Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation. J Arrhythm (2015) 0.77
Clinical evaluation of laboratory methods to monitor exposure of rivaroxaban at trough and peak in patients with atrial fibrillation. Eur J Clin Pharmacol (2016) 0.77
Results expression for tests used to measure the anticoagulant effect of new oral anticoagulants. Thromb J (2013) 0.77
A clinician's perspective: novel oral anticoagulants to reduce the risk of stroke in nonvalvular atrial fibrillation--full speed ahead or proceed with caution? Vasc Health Risk Manag (2014) 0.77
New anticoagulants: pharmacology and clinical studies. Wien Med Wochenschr (2011) 0.77
Monitoring of direct anticoagulants. Wien Med Wochenschr (2011) 0.77
Practical Issues to Prevent Stroke Associated with Non-valvular Atrial Fibrillation. J Stroke (2013) 0.77
Management of anticoagulant-related intracranial hemorrhage: an evidence-based review. Crit Care (2014) 0.76
Global assays and the management of oral anticoagulation. Thromb J (2015) 0.76
Main considerable factors for correct laboratory test interpretation under DOA treatment. Thromb J (2013) 0.75
Warfarin and Rivaroxaban Duplication: A Case Report and Medication Error Analysis. Drug Saf Case Rep (2015) 0.75
Balancing efficacy and bleeding risk in the prevention of stroke due to atrial fibrillation with newer oral anticoagulants. Indian J Hematol Blood Transfus (2012) 0.75
Anticoagulation Reversal and Treatment Strategies in Major Bleeding: Update 2016. West J Emerg Med (2016) 0.75
Evaluation of the Antithrombotic Effects of Rivaroxaban and Apixaban Using the Total Thrombus-Formation Analysis System(®): In Vitro and Ex Vivo Studies. J Clin Med Res (2016) 0.75
Population Pharmacokinetic and Pharmacodynamic Modeling Analysis of GCC-4401C, a Novel Direct Factor Xa Inhibitor, in Healthy Volunteers. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
New oral anticoagulants - a practical guide. Kardiochir Torakochirurgia Pol (2015) 0.75
Novel oral anticoagulants for venous thromboembolism prophylaxis after total hip or knee replacement: an update on rivaroxaban (xarelto). P T (2013) 0.75
Introduction to haemostasis from a pharmacodynamic perspective. Br J Clin Pharmacol (2011) 0.75
Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies. Br J Clin Pharmacol (2015) 0.75
Patient Taking A Novel Oral Anticoagulant Presents With Major GI Bleeding. J Atr Fibrillation (2015) 0.75
Rivaroxaban as an oral anticoagulant for stroke prevention in atrial fibrillation. Ther Clin Risk Manag (2014) 0.75
Trends in physiological coagulation factors in Japanese patients receiving novel oral anticoagulants. J Arrhythm (2016) 0.75
Pharmacokinetics and Pharmacodynamics of the Nonvitamin K Antagonist Oral Anticoagulant Edoxaban When Administered Alone or After Switching from Rivaroxaban or Dabigatran Etexilate in Healthy Subjects. Clin Drug Investig (2016) 0.75
Correction of Point-of-Care INR Results in Warfarin Patients. Point Care (2016) 0.75
Advances in oral anticoagulation treatment: the safety and efficacy of rivaroxaban in the prevention and treatment of thromboembolism. Ther Adv Hematol (2012) 0.75
Use of rivaroxaban in patients with stroke. Neurol Sci (2017) 0.75
Direct Oral Anticoagulants Form Thrombus Different From Warfarin in a Microchip Flow Chamber System. Sci Rep (2017) 0.75
Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation (2007) 3.17
Laboratory assessment of new anticoagulants. Clin Chem Lab Med (2011) 1.99
NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle. Br J Pharmacol (2002) 1.90
Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet (2003) 1.88
Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ (2008) 1.78
Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol (2009) 1.73
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost (2011) 1.47
Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials. Menopause (2014) 1.46
Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause (2010) 1.45
Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause (2011) 1.41
Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3- [4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene- 2-carboxamide (BAY 59-7939): an oral, direct factor Xa inhibitor. J Med Chem (2005) 1.40
Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors. Hum Reprod (2011) 1.26
Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol (2002) 1.26
Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol (2002) 1.20
The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression. PLoS One (2009) 1.17
Laboratory assessment of rivaroxaban: a review. Thromb J (2013) 1.16
Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res (2006) 1.13
Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thromb Res (2013) 1.02
Hemostatic therapy in experimental intracerebral hemorrhage associated with rivaroxaban. Stroke (2013) 0.99
Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost (2012) 0.99
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost (2012) 0.97
Benign breast diseases. J Mammary Gland Biol Neoplasia (2005) 0.95
An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma. Thromb Haemost (2010) 0.95
In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res (2011) 0.93
A role for coagulation factor Xa in experimental pulmonary arterial hypertension. Cardiovasc Res (2011) 0.90
High level of plasma estradiol as a new predictor of ischemic arterial disease in older postmenopausal women: the three-city cohort study. J Am Heart Assoc (2012) 0.89
Progestogen-only contraceptives and the risk of stroke: a meta-analysis. Stroke (2009) 0.89
Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci (2013) 0.86
Do new oral anticoagulants require laboratory monitoring? The clinician point of view. Thromb Res (2012) 0.86
Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy? Thromb Haemost (2009) 0.86
Measurement of dabigatran and rivaroxaban in primary prevention of venous thromboembolism in 106 patients, who have undergone major orthopedic surgery: an observational study. J Thromb Thrombolysis (2013) 0.86
Prevention and treatment of experimental thrombosis in rabbits with rivaroxaban (BAY 597939)--an oral, direct factor Xa inhibitor. Thromb Haemost (2007) 0.85
Arterial antithrombotic activity of rivaroxaban, an orally active factor Xa inhibitor, in a rat electrolytic carotid artery injury model of thrombosis. Blood Coagul Fibrinolysis (2011) 0.85
Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. Atherosclerosis (2003) 0.84
Progestogen-only contraception in women at high risk of venous thromboembolism. Contraception (2004) 0.84
Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma. Blood Coagul Fibrinolysis (2004) 0.84
Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation (2005) 0.83
The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost (2004) 0.83
Preclinical and clinical characteristics of rivaroxaban: a novel, oral, direct factor Xa inhibitor. Semin Thromb Hemost (2007) 0.83
Effects of oral and transvaginal ethinyl estradiol on hemostatic factors and hepatic proteins in a randomized, crossover study. J Clin Endocrinol Metab (2007) 0.82
Recombinant factor VIIa partially reverses the inhibitory effect of fondaparinux on thrombin generation after tissue factor activation in platelet rich plasma and whole blood. Thromb Haemost (2004) 0.82
Monitoring plasma levels of factor Xa inhibitors: how, why and when? Expert Rev Hematol (2013) 0.82
Progestogen-only contraceptives and the risk of acute myocardial infarction: a meta-analysis. J Clin Endocrinol Metab (2011) 0.82
Influence of hormonal control on LH pulsatility and secretion in women with classical congenital adrenal hyperplasia. Eur J Endocrinol (2012) 0.81
Progestogens and venous thromboembolism among postmenopausal women using hormone therapy. Maturitas (2011) 0.80
The discovery and development of rivaroxaban. Ann N Y Acad Sci (2011) 0.80
Comparison of unfractionated heparin, low-molecular-weight heparin, low-dose and high-dose rivaroxaban in preventing thrombus formation on mechanical heart valves: results of an in vitro study. J Thromb Thrombolysis (2011) 0.80
Postmenopausal hormone therapy and cardiovascular disease: an overview of main findings. Maturitas (2006) 0.80
Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone. Br J Haematol (2003) 0.77
Death-associated protein kinase loss of expression is a new marker for breast cancer prognosis. Clin Cancer Res (2004) 0.77
Proteomics of methylene blue photo-treated plasma before and after removal of the dye by an absorbent filter. Proteomics (2004) 0.77
Estrogen plus progestin and risk of venous thrombosis. JAMA (2005) 0.75
Lung cancer and hormone replacement therapy. Lancet (2010) 0.75
The discovery of rivaroxaban: translating preclinical assessments into clinical practice. Front Pharmacol (2013) 0.75
Risk assessment for recurrent venous thrombosis. Lancet (2011) 0.75
First venous thromboembolism and hormonal contraceptives in young French women. Medicine (Baltimore) (2017) 0.75
On the mechanism of inhibition of tissue factor pathway by the synthetic pentasaccharide during coagulation of human plasma. Blood Coagul Fibrinolysis (2003) 0.75
Hormonal contraception in women at risk of vascular and metabolic disorders: guidelines of the French Society of Endocrinology. Ann Endocrinol (Paris) (2012) 0.75
[Difficult contraceptions]. Rev Prat (2008) 0.75